News | May 28, 2024
AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Establishing Asymchem’s first manufacturing footprint in Europe
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Around 7% of the Indian population suffers from IBS
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Subscribe To Our Newsletter & Stay Updated
